靶向GPRC5DxCD3的双特异性抗体治疗多发性骨髓瘤
本文报道了一种靶向GPRC5D和CD3的双特异性抗体JNJ-64407564,可招募CD3+ T细胞杀伤GPRC5D+骨髓瘤细胞。体外实验显示该抗体诱导GPRC5D+细胞特异性细胞毒作用并激活T细胞,也杀伤骨髓瘤患者样本中的浆细胞;小鼠模型中可招募T细胞并诱导肿瘤消退。GPRC5D是有前景的骨髓瘤免疫治疗表面抗原,该抗体正在复发/难治性多发性骨髓瘤患者中进行1期临床试验(NCT03399799)。
要点
- GPRC5D在多发性骨髓瘤和冒烟型骨髓瘤患者浆细胞中表达,其蛋白存在于骨髓瘤细胞表面。
- JNJ-64407564是GPRC5DxCD3双特异性抗体,可招募CD3+ T细胞杀伤GPRC5D+骨髓瘤细胞。
- 该抗体正在复发/难治性多发性骨髓瘤患者中开展1期临床试验(NCT03399799)。
核心结论
- GPRC5D是有前景的多发性骨髓瘤免疫治疗表面抗原,JNJ-64407564正在复发/难治性多发性骨髓瘤患者中进行1期临床试验(NCT03399799)。
研究设计与样本
- 临床前研究,评估GPRC5DxCD3双特异性抗体JNJ-64407564的体外和体内活性。
主要发现
- GPRC5D蛋白存在于骨髓瘤细胞表面。
- 体外JNJ-64407564诱导GPRC5D+细胞特异性细胞毒作用并伴随T细胞激活,也杀伤骨髓瘤患者样本中的浆细胞。
- 在GPRC5D+骨髓瘤小鼠模型中,JNJ-64407564可招募T细胞并诱导肿瘤消退,与肿瘤部位T细胞浸润一致。
- 该抗体能诱导来自骨髓的患者原代骨髓瘤细胞产生细胞毒作用。
临床怎么用
- GPRC5D可作为多发性骨髓瘤免疫治疗的候选靶点,JNJ-64407564尚处于1期临床试验阶段。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T-cell-mediated approaches have shown promise in myeloma treatment. However, there are currently a limited number of specific myeloma antigens that can be targeted, and multiple myeloma (MM) remains an incurable disease. G-protein-coupled receptor class 5 member D (GPRC5D) is expressed in MM and smoldering MM patient plasma cells. Here, we demonstrate that GPRC5D protein is present on the surface of MM cells and describe JNJ-64407564, a GPRC5DxCD3 bispecific antibody that recruits CD3+ T cells to GPRC5D+ MM cells and induces killing of GPRC5D+ cells. In vitro, JNJ-64407564 induced specific cytotoxicity of GPRC5D+ cells with concomitant T-cell activation and also killed plasma cells in MM patient samples ex vivo. JNJ-64407564 can recruit T cells and induce tumor regression in GPRC5D+ MM murine models, which coincide with T-cell infiltration at the tumor site. This antibody is also able to induce cytotoxicity of patient primary MM cells from bone marrow, which is the natural site of this disease. GPRC5D is a promising surface antigen for MM immunotherapy, and JNJ-64407564 is currently being evaluated in a phase 1 clinical trial in patients with relapsed or refractory MM (NCT03399799).
引用
- Pillarisetti K, Edavettal S, Mendonça M, et al. A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood. 2020. PMID: 32040549. doi:10.1182/blood.2019003342
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。